OSE Immunotherapeutics Reports Positive Phase 2 Combi-TED Results
OSE Immunotherapeutics said the primary endpoint was met. One-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab, versus 29% with docetaxel alone; no unexpected safety signals were reported. Final data are due Oct. 25, 2026, at ESMO.